The optionMONSTER.com co-founder discusses what companies he thinks will soon pop and why.

Following reports that Sanofi-Aventis could offer $20 billion for Genzyme, the traders discuss ways to play the possible take-over without "sticking your neck out."

Google says people in mainland China are being blocked from using its Internet search engine. 

Brian Stutland of CBOE Partners brings you Thursday's Options Action.

Where’s the fast money finding opportunity? Anthony Scaramucci aka The Hedge reveals his latest greatest pick!

Facing fierce challenges from Apple's iPad, on Thursday Amazon made a surprise move that they say could get people to buy Kindles for the entire family!

While one might think travel and leisure businesses would have taken a hit during the recession, this company shows signs of smooth sailing.

Cantor Fitzgerald's Mike Khouw has Wednesday's Options Action, where he's making a bullish bet on this energy company.

A famed stock picker is telling clients to run with the tiger and buy Exxon. Should you do the same?

Investors are struggling to determine if the market has topped out and the next leg is lower – or if the market is at a consolidation point with further gains to follow.

Fast Money friend Dennis Gartman says earnings estimates come and go, but companies increasing dividends might be a better guide to a company's health.

Considering shares of Merck are little changed over the past 3 months, how should you game this stock ahead of earnings, Friday?

Aren’t you bored with summer fun in the sun? Our traders can hardly wait to say goodbye to the Hamptons and hello to cold winter weather.

As one of the last industrial management companies to report, how should you game Waste Management?

While it may feel like a value opportunity, Bernstein’s Colin McGranahan says Best Buy is more likely a value trap.

What must you know about Windstream before you place a bet? Don’t make a move until you see our interview with CEO Jeffrey Gardner.

Considering shares of Radio Shack are down about 10% over the past 3 months, how should you game this stock ahead of earnings, Thursday?

The traders are closely watching the action in Sprint, which reports earnings Wednesday. If you think Sprint doesn’t matter, think again!

If Genzyme is in play, the top biotech analyst on the Street thinks the stock could go to $80.

With earnings rapidly approaching we updated this post with even more trades! How should you game Boeing ahead of earnings Wednesday?